Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bazedoxifene + eldecalcitol
- Development stage
- Unknown
- Lead developer
- Shinshu University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of bazedoxifene, a third-generation selective estrogen receptor modulator (SERM), and eldecalcitol, an active vitamin D3 analog. Bazedoxifene (Viviant) acts as an estrogen receptor agonist in bone, effectively inhibiting bone resorption and maintaining bone mineral density without stimulating the endometrium or breast tissue. Eldecalcitol (Edirol) is a vitamin D receptor agonist that enhances intestinal calcium absorption and further suppresses bone resorption. The combination is specifically being investigated by Shinshu University in a Phase 2 clinical trial as a sequential therapy for Japanese patients with osteoporosis who have previously received denosumab, aiming to prevent the rapid bone loss and increased fracture risk often observed after denosumab discontinuation.
- Brand names
- Viviant + Edirol
- Other names
- bazedoxifene acetate + eldecalcitolSERM + ELDbazedoxifene plus eldecalcitol
02
Targets
ESR2 (ERβ)ESR1 (ERα)
Beyond the preview
Go deeper on bazedoxifene + eldecalcitol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bazedoxifene + eldecalcitol.